Primary intestinal lymphangiectasia successfully treated with octreotide

被引:70
作者
Kuroiwa, G [1 ]
Takayama, T [1 ]
Sato, Y [1 ]
Takahashi, Y [1 ]
Fujita, T [1 ]
Nobuoka, A [1 ]
Kukitsu, T [1 ]
Kato, J [1 ]
Sakamaki, S [1 ]
Niitsu, Y [1 ]
机构
[1] Sapporo Med Univ, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
关键词
octreotide; lymphangiectasia; protein-losing enteropathy;
D O I
10.1007/s005350170142
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A 21-year-old man with diarrhea and edema was admitted to our hospital and diagnosed with protein-losing enteropathy caused by primary intestinal lymphangiectasia. He was placed, in turn, on a low-fat diet, an elemental diet, and, subsequently, fasting therapy with total parenteraI nutrition (TPN) support. However, his symptoms were not relieved, but, rather were exacerbated. On the 45th day of hospitalization octreotide therapy was initiated. After 2 weeks of treatment, his clinical symptoms, as well as hypoproteinemia and hypoalbuminemia, gradually became alleviated. The improvement was confirmed in terms of scintigraphy, endoscopy, and histology of the duodenum. The patient remained healthy until 6 months after the commencement of octreotide treatment, when he discontinued octreotide at his own discretion, at which point the symptoms recurred. Resumption of the drug; however, again brought about remission, which has continued until the present, March 2000. Thus, octreotide therapy is one modality which may be useful for refractory primary intestinal lymphangiectasia.
引用
收藏
页码:129 / 132
页数:4
相关论文
共 9 条
[1]   OCTREOTIDE FOR PROTEIN-LOSING ENTEROPATHY WITH INTESTINAL LYMPHANGIECTASIA [J].
BAC, DJ ;
VANHAGEN, PM ;
POSTEMA, PTE ;
TENBOKUM, AMC ;
ZONDERVAN, PE ;
VANBLANKENSTEIN, M .
LANCET, 1995, 345 (8965) :1639-1639
[2]  
Ballinger AB, 1998, EUR J GASTROEN HEPAT, V10, P699
[3]   SOMATOSTATIN INHIBITS RELEASE OF ACETYLCHOLINE INDUCED ELECTRICALLY IN MYENTERIC PLEXUS [J].
GUILLEMIN, R .
ENDOCRINOLOGY, 1976, 99 (06) :1653-1654
[4]  
HARRIS AG, 1992, DRUG INVEST, V4, P1
[5]   Drug therapy - Octreotide [J].
Lamberts, SWJ ;
vanderLely, AJ ;
deHerder, WW ;
Hofland, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (04) :246-254
[6]   EFFECT OF SOMATOSTATIN ON THE FLOW-RATE AND TRIGLYCERIDE LEVELS OF THORACIC-DUCT LYMPH IN NORMAL AND VAGOTOMIZED DOGS [J].
NAKABAYASHI, H ;
SAGARA, H ;
USUKURA, N ;
YOSHIMITSU, K ;
IMAMURA, T ;
SETA, T ;
YANASE, E ;
KAWATO, M ;
HIRAIWA, Y ;
SAKATO, S ;
TAKEDA, R .
DIABETES, 1981, 30 (05) :440-445
[7]   SOMATOSTATIN .1. [J].
REICHLIN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (24) :1495-1501
[8]   SOMATOSTATIN .2. [J].
REICHLIN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (25) :1556-1563
[9]   REDUCTION OF LYMPHORRHAGIA FROM RUPTURED THORACIC-DUCT BY SOMATOSTATIN [J].
ULIBARRI, JI ;
SANZ, Y ;
FUENTES, C ;
MANCHA, A ;
ARAMENDIA, M ;
SANCHEZ, S .
LANCET, 1990, 336 (8709) :258-258